Panacea Life Sciences Holdings Inc · OTC:PLSH
Panacea Life Sciences — Investor Presentation (May 2022)
31 slides from Panacea Life Sciences's investor presentation, May 3, 2022
Slide 1: Panacea Life Sciences Investor Presentation May 2022
panacealife.com | OTCQB: PLSH Panacea Life Sciences May 2022 Investor Presentation
Slide 2: Disclaimer
— Disclaimer This Presentation (the “Presentation”) has been prepared solely for informational purposes by Company and any individuals mentioned in the Presentation (together, “Company”) and is being furnished solely for use by prospective investors and other third parties in connection with their c
Slide 3: Emerging as a leading seed-to-sale cannabinoid company
Emerging as a leading seed-to-sale cannabinoid company focused on leveraging scientific expertise, partnerships and data to provide high quality, pharmaceutical grade products to the health and wellness and nutraceutical markets.
Slide 4: Investment Highlights
Investment Highlights Fully-Integrated Cannabinoid Based Business Focused on providing portfolio of high-end products for humans and companion animals Leveraging Internal Scientific R&D Expertise Enhance and bolster current and expanding product portfolios cGMP Manufacturing Facility Operating withi
Slide 5: The CBD Market Is Rapidly Expanding
—— The CBD Market Is Rapidly Expanding Establishing Leadership Position in New and Evolving CBD Market ~64 Million people have tried CBD in the last 24 months? S2.7 Billion market valued in 20202 S20 Billion market expected to surpass by 20242 51% CARGR market expected to grow from 2021 to 20302 201
Slide 6: Growing a High-End Consumer Cannabinoid Brand
Growing a High-End Consumer Cannabinoid Brand Providing Solutions with an Emphasis on Quality, Purity and Benefits Health Beauty Sports Companion Raw Materials Animal
Slide 7: PANA Health
——— PANA HEALTH Organic Cannabinoid Products Designed to Support Everyday Wellness “PANA | “Pp cc ol SOFTGELS TABLETS TINCTURES TOPICALS Full Spectrum Broad Spectrum THC-Free
Slide 8: PANA Beauty
—— PANA BEAUTY High-End CBD Products To Support Healthier Skin Dermatologist Created and Approved MOISTURIZING FACE MOISTURE EYE SKIN CREAM CREAM THERAPY THERAPY CLEARING Anti-Inflammatories Free Radical-Fighting Antioxidants Free of Sulfates and Parabens
Slide 9: PANA Sport
PANA SPORT Designed to Keep Athletes at Any Level At the Top of Their Game HEALING COOLING HEALING COOLING K STICK STICK PATCHES PATCHES TAPE Designed to Provide Long-Lasting Relief from Muscle and Joint Aches and Pains
Slide 10: PANA Life
—— PANA LIFE Daily CBD Wellness Gummies and Lip Balm GUMMIES GUMMIES LIP TO-GO SOOTHE All-Natural Full Spectrum Gummies Designed to Provide Health Benefits
Slide 11: PANA Pure
PANA PURE CBD CRUDE | CBD DISTILLATE | DISTILLATE BLENDS | CBG | CBN | CBDA
Slide 12: PANA Pet
—— PANA PET Aim To Relieve Joint Pain, Inflammation and Anxiety in Cats, Dogs and Horses Semen era OIL RELIEF EQUINE CALMOLYTE SOIREGIEES DROPS CREAM MINT HORSE PAST Created with Input from Veterinarians
Slide 13: Significant Growth Opportunity in Nutraceuticals
Significant Growth Opportunity in Nutraceuticals Consumers are actively searching for pharmaceutical alternatives with medical benefits market expected to grow to by 20281 Gaining popularity with rising awareness of health benefits
Slide 14: PANA Nutraceuticals
— PANA Nutraceuticals Purposeful Formulations Leveraging Science, Data and Expertise a EAL CANNABIDIOL CBDA PM SLEEP CBD+CBG ORAL SOLUTION OIL DROPS SOFTGELS DERMA SOOTHE Purposely formulated to help Supports your vital Fall asleep faster, and Reduce and soothe skin alleviate more long-term and immu
Slide 15: Proven Quality Through Partnership with Colorado State University
—— Proven Quality Through bata _____ @ Partnership with Colorado State University Unitizing data and proven expertise to develop new high-quality products Harnessing additionally hemp benefits through CBG, CBC, CBN, etc. Setting the industry quality standard through testing equipment and chromatogra
Slide 16: On-Going Research Studies for Pharmaceutical Alternatives
On-Going Research Studies for Pharmaceutical Alternatives Near-Term Opportunities to Provide Solutions in Areas of High-Value and Unmet Need Method Development: Removal of pesticides, isolation of CBDV, CBC Animal Studies Human Clinical Studies McGrath and Moreno (CSU): CBD and Reynolds (CSU) Crews
Slide 17: Sales Channels and Market Accessibility
—— Sales Channels and Market Accessibility Online Direct to Consumers White Label/Contract Mfg. Retail/Wholesale ~35% of total sales ~45% of total sales ~20% of total sales Established online presence Trusted Manufacturing 1100 Retail locations Source Natural retail chains Direct to consumer eCommer
Slide 18: Growing the Brand Through Robust Marketing Efforts
——— Growing the Brand Through Robust Marketing Efforts — Details Around Marketing ar Paid oan DMA Focused . mall Advertising fon Trusted SLOPE ZWs Campaigns Personalities Tom Martino Tony Lombardi Social Athlete Social Tradeshows Influencers Influencers Media Instagram Cosmetic Twitter Industry Spec
Slide 19: Opportunity to Expand Into Complementary Verticals
——— Opportunity to Expand Into Complementary Verticals — Attack Adjacent Industries Current US Market Size Sales (Billions of $) Personal care $433 Packaged Food $377 Pharmaceuticals $333 Animal Feed $170 Alcoholic Beverages $212 Pet Food $127 Tobacco $93 Supplements $65 Cannabis $25 @ Personal care
Slide 20: Using the Highest Quality Raw Materials
Using the Highest Quality Raw Materials Hemp from Colorado based PANA Organic Botanicals at Needle Rock Tested for quality, potency and purity Pesticides, herbicides, heavy metals and microbials Grown in ideal environment with access to Rocky Mountain spring water
Slide 21: State-Of-The-Art 51,000 sq.ft cGMP Manufacturing Facility
State-Of-The-Art 51,000 sq.ft cGMP Manufacturing Facility Producing High Quality, Pharmaceutical Grade Products — Total capacity — Weekly CBD oil extraction and production capability — Daily softgel production — Liquid fills per day In-house bottling and labeling Fulfillment Services cGMP Certificat
Slide 22: Testing and Production Process
Test Seeds Receive Test Extract Test Process to Test Process to & Soil Hemp Hemp Crude Oil Crude Oil Distillate Distillate CBD Isolate Test Seeds Develop Test Finalize Certificate Bottle & Distribute Isolate Formulation Formulation Product of Analysis Label
Slide 23: Fully Integrated SAP ERP System
—— Fully Integrated SAP ERP System FINANCE/ACCOUNTING | INVENTORY CONTROLS AND VENDOR MANAGEMENT HUMAN RESOURCES | PRODUCTION PLANNING Streamline Business . . Integrate Payroll and Provide Tracking of . Processes and laventemantovesaent Production Costs Measurement Points "y Monitoring PROVIDES PANA
Slide 24: Business Development, Financials and Team
Business Development, Financials and Team
Slide 25: Potential for Multiple Near-Term Growth Opportunities
Potential for Multiple Near-Term Growth Opportunities Expand Current Business Leveraging Existing Assets Grow current brands through Sell excess cGMP robust marketing efforts manufacturing capabilities Develop natural, purposeful White label and contract products under Panacea brand manufacturing se
Slide 26: Balance Sheet (Historical)
Balance Sheet (Historical) Panacea Life Sciences Holding, Inc. and Subsidiary Consolidated Balance Sheet December 31, 2021 December 31, 2020 December 31, 2019 December 31, 2018 TOTAL CURRENT ASSETS 9,098,358 eS 22227) 14,965,410 5,096,187 TOTAL ASSETS $ 23,783,651 $ 31,361,830 $ 32,553,803 $ 7,875,3
Slide 27: Income Statement (Historical)
—— Income Statement (Historical) Panacea Life Sciences Holding, Inc. and Subsidiary Consolidated Statements of Operations for the years ending December 31, 2021 2020 2019 2018 REVENUE $ 2,059,627 $ 9,017,720 $ 2,198,408 $ 1,099,704 COST OF SALES 1,519,049 7,020,223 1,785,665 349,564 GROSS PROFIT 540
Slide 28: Proven Leadership Team
—— Proven Leadership Team Leslie Buttorff Chief Executive Officer & Chairman Over 35 years as a senior executive in management, marketing, technical evaluations, and financial analyses at companies such as AT Kearny, Arthur D. Little and EDS (HP) Nick Cavarra SVP Sales & Marketing Over 25 years of m
Slide 29: Advancements Through Scientific Expertise
—— Advancements Through Scientific Expertise Scientific Advisory Board Melissa Reynolds, PhD Analytical Chemist, Head of CRC Head of the Panacea Cannabinoid Research Center at CSU Nathan Morris, MD General Practitioner Highly regarded holistic doctor and actual customer of Panacea Janice Knox, MD Ge
Slide 30: Investment Summary
Investment Summary Emerging as a Leading Seed-to-Sale Cannabinoid Company Leveraging scientific innovation, research and data to provide high-quality, pharmaceutical grade products Growing a high-end consumer cannabinoid brand focused on quality, purity and benefits Unlocking potential value with ex
Slide 31: panacealife.com
panacealife.com | OTCQB: PLSH Panacea Life Sciences IR Contact: JTC Team, Inc. 833.475.8247
Panacea Life Sciences Holdings — Investor Presentation (May 2022) on 6ix